Crinetics Pharmaceuticals, Inc. (CRNX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 7, 2026, relates to Crinetics Pharmaceuticals, Inc., a Delaware corporation headquartered in San Diego, California. The filing reports financial results for the period ended March 31, 2026, via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text serves as a cover document referencing a press release but does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the period ended March 31, 2026.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this Form 8-K. The document solely announces the issuance of the financial results press release.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information in the press release (Exhibit 99.1) is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, management commentary, risks, or unusual items are described within the body of this 8-K text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 7, 2026) for actual financial figures and operational updates.
- Verify the specific revenue and net loss figures for the quarter ended March 31, 2026, as they are not present in this summary document.
- Check for updated cash runway and burn rate details in the attached press release.
- Confirm any new clinical trial milestones or regulatory updates mentioned in the full press release.